[4][5][6] In 2011, Alex Zhavoronkov published an article in the journal PLOS One with Dr. Charles Cantor, previously director of the Human Genome Project at the Department of Energy (DOE) and founder of Sequenom on the International Aging Research Portfolio (IARP), establishing a public data set tracking government research funding and outcomes.

[16] By mid-2017, Insilico had raised $8.26 million in funding from investors including Deep Knowledge Ventures, JHU A-Level Capital,[17] Jim Mellon,[18] and Juvenescence.

[23] Later in 2021 after developing a novel preclinical candidate molecule for a novel target,[24] the company announced a series C $255 million megaround [25] from Warburg Pincus, Sequoia Capital, Orbimed, Mirae Asset Financial Group, and over 25 biotechnology, AI, and pharmaceutical investors.

[28] In 2023, Zhavoronkov stated that he "moved the company's R&D to China to capitalize on 'half a trillion dollars' worth of infrastructure and hundreds of thousands of scientists [provided by the government] to enable AI-designed drugs".

[23] To demonstrate the capacity of their proprietary AI platforms, the company published two projects on identifying therapeutic targets for ageing[33] and amyotrophic lateral sclerosis[34] in 29 March and 28 June 2022, respectively.

[36] In 2023, it was reported that Insilico had initiated "one of the first mid-stage human trials of a drug discovered and designed by artificial intelligence".